However, in contrast to the results obtained in uterine cancer, where a specific activity of GSK2256098 (FAK inhibitor) was demonstrated in PTEN-mutated compared to wild-type cancer cells [24], we found that defactinib was equally efficient in SCC cells with low PTEN levels compared to parental cells. This evidence concerns the gene PTK2 and uterine cancer.